Serum anti-hsp27 antibodies concentration in diabetes mellitus; population based case-control study
Archives of Medical Laboratory Sciences,
Vol. 5 No. 1 (2019),
29 March 2020
,
Page 12-17
https://doi.org/10.22037/amls.v5i1.30140
Abstract
Background: Diabetes mellitus is an important risk factor for cardiovascular disease. Different biomarkers have been investigated for the diagnosis of diabetes pathogenesis or its complications. There are also reports regarding an increased level of anti-HSP27 antibodies in atherogenesis. We aimed to evaluate serum anti-heat shock protein 27 antibodies level in subjects with diabetes mellitus and undiagnosed individuals.
Materials and Methods: This cross-sectional study was conducted on 6447 MASHAD study subjects, including four groups with diabetes mellitus (n=610), undiagnosed diabetes (n=162), impaired fasting glucose (IFG) (n=619) and normal (n=5056) subjects. Demographic and anthropometric data were obtained from all participants. Fasting serum glucose (FSG) and other parameters were measured. In-house enzyme-linked immune sorbent assay method was used for measuring Anti-HSP27 antibodies levels.
Results: There were significant differences in weight (p=0.034), body mass index, waist, and hip circumference, systolic and diastolic blood pressure, fasting serum glucose, lipid profile and high sensitive- C reactive protein (p<0.001) between four groups of diabetes mellitus, undiagnosed diabetes, impaired fasting glucose, and normal subjects. The serum anti-HSP27 antibody titer did not show a significant difference between studied groups.
Conclusion: Serum antibody titers to HSP27 were not significantly different between four groups categorized based on their FSG levels in a large population.
- anti-HSP27 antibody, Diabetes mellitus, MASHAD study cohort
How to Cite
References
Association AD. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014;37(Supplement 1):S81-S90.
Jakhotia S, Sivaprasad M, Shalini T, Reddy PY, Viswanath K, Jakhotia K, et al. Circulating levels of Hsp27 in microvascular complications of diabetes: Prospects as a biomarker of diabetic nephropathy. Journal of diabetes and its complications. 2018;32(2):221-5.
Wright Jr E, Scism‐Bacon J, Glass L. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. International journal of clinical practice. 2006;60(3):308-14.
Hooper PL, Hooper PL. Inflammation, heat shock proteins, and type 2 diabetes. Cell Stress and Chaperones. 2009;14(2):113-5.
Hightower LE. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell. 1991;66(2):191-7.
Xu Q. Role of heat shock proteins in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2002;22(10):1547-59.
Sahebkar A, Pourghadamyari H, Moohebati M, Parizadeh SMR, Falsoleiman H, Dehghani M, et al. A cross-sectional study of the association between heat shock protein 27 antibody titers, pro-oxidant–antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease. Clinical biochemistry. 2011;44(17-18):1390-5.
Rayner K, Chen Y-X, Siebert T, O'Brien ER. Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection? Trends in cardiovascular medicine. 2010;20(2):53-7.
Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis & tissue repair. 2012;5(1):7.
Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cellular and molecular life sciences. 2009;66(20):3289-307.
Park HK, Park E-C, Bae SW, Park MY, Kim SW, Yoo HS, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation. 2006;114(9):886-93.
Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes. 2008;57(7):1966-70.
Burt D, Bruno G, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, et al. Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study. Diabetes Care. 2009;32(7):1269-71.
Burut DFP, Borai A, Livingstone C, Ferns G. Serum heat shock protein 27 antigen and antibody levels appear to be related to the macrovascular complications associated with insulin resistance: a pilot study. Cell Stress and Chaperones. 2010;15(4):379-86.
Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clinica Chimica Acta. 2008;395(1-2):42-6.
Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. International journal of public health. 2015;60(5):561-72.
Bansal N. Prediabetes diagnosis and treatment: A review. World journal of diabetes. 2015;6(2):296.
Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes/metabolism research and reviews. 2000;16(4):230-6.
Gomez-Pastor R, Burchfiel ET, Thiele DJ. Regulation of heat shock transcription factors and their roles in physiology and disease. Nature Reviews Molecular Cell Biology. 2018;19(1):4.
Habich C, Sell H. Heat shock proteins in obesity: links to cardiovascular disease. Hormone molecular biology and clinical investigation. 2015;21(2):117-24.
Kargari M, Parizadeh SMR, Karimian MS, Farahmand SK, Sahebkar A, Esmaeili H, et al. Serum anti-HSP27 antibody titers in patients with metabolic syndrome, with or without diabetes mellitus. Comparative Clinical Pathology. 2016;25(4):895-901.
- Abstract Viewed: 146 times
- pdf Downloaded: 67 times